rs,
5 November 2022 Corporate Service Department BSE Limited 25 th Floor, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai 400001 The Listing Department National Stock Exchange of India Ltd Exchange
10.6%
ue growth[1] with EBITDA growing sequentially across all regions 1 2 3 4 5 Revenue growth of 10.6% [2] at constant currency broad based across all regions, despite continued impact of Covid lockdow
17.7%
tinued impact of Covid lockdowns in EAP Revenue growth led by ‘Personal Care & beyond’* growing at 17.7% with revenue composition at 48% of total (YoY increase of 243 bps) EBITDA margin @ 16.3% [3], seq
48%
EAP Revenue growth led by ‘Personal Care & beyond’* growing at 17.7% with revenue composition at 48% of total (YoY increase of 243 bps) EBITDA margin @ 16.3% [3], sequential improvement of 119 bps an
243 bps
ersonal Care & beyond’* growing at 17.7% with revenue composition at 48% of total (YoY increase of 243 bps) EBITDA margin @ 16.3% [3], sequential improvement of 119 bps and sequential EBITDA growth of 22.
16.3%
owing at 17.7% with revenue composition at 48% of total (YoY increase of 243 bps) EBITDA margin @ 16.3% [3], sequential improvement of 119 bps and sequential EBITDA growth of 22.9% on the back of strong
119 bps
ion at 48% of total (YoY increase of 243 bps) EBITDA margin @ 16.3% [3], sequential improvement of 119 bps and sequential EBITDA growth of 22.9% on the back of strong pricing actions, despite continued raw
22.9%
bps) EBITDA margin @ 16.3% [3], sequential improvement of 119 bps and sequential EBITDA growth of 22.9% on the back of strong pricing actions, despite continued raw material inflation, currency devaluat
9.0%
very by end of FY23 [1] at constant currency [2] reported revenue growth at actual currency rate @ 9.0% [3] EBITDA margin @ 16.1% including Brazil * Personal Care and beyond includes Beauty & Cosmetics,
16.1%
t constant currency [2] reported revenue growth at actual currency rate @ 9.0% [3] EBITDA margin @ 16.1% including Brazil * Personal Care and beyond includes Beauty & Cosmetics, Pharma etc. 4 4 EPL Lim
13.1%
from Operations EBITDA and EBITDA Margins EBIT and EBIT Margins 8,701 9.0% 9,481 Excl EAP 13.1% 18.3% 1,594 16.3% 1,544 -3.1% 11.2% 972 9.3% 884 -9.1% Q2FY22 Q2FY23 Q2FY22 Q2FY23
18.3%
perations EBITDA and EBITDA Margins EBIT and EBIT Margins 8,701 9.0% 9,481 Excl EAP 13.1% 18.3% 1,594 16.3% 1,544 -3.1% 11.2% 972 9.3% 884 -9.1% Q2FY22 Q2FY23 Q2FY22 Q2FY23 Q2FY2